-
-
[1] Longcope C. Adrenal and gonadal androgen secretion in normal females[J]. Clin Endocrinol Metab, 1986, 15:213-228. doi: 10.1016/S0300-595X(86)80021-4 [2] Burger HG. Androgen production in women[J]. Fertil Steril, 2002, 77 Suppl 4:S3-S5. http://europepmc.org/abstract/med/12007895 [3] Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women:role of the ovary?[J]. Menopause, 2011, 18:30-43. doi: 10.1097/gme.0b013e3181e195a6 [4] Labrie F, Belanger A, Cusan L, et al. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging[J]. J Clin Endocrinol Metab, 1997, 82:2396-2402. doi: 10.1210/jcem.82.8.4160 [5] Labrie F, Luu-The V, Labrie C, et al. DHEA and its transformation into androgens and estrogens in peripheral target tissues:intracrinology[J]. Front Neuroendocrinol, 2001, 22:185-212. doi: 10.1006/frne.2001.0216 [6] Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women:strong lesson for hormone therapy of prostate and breast cancer[J]. J Steroid Biochem Mol Biol, 2009, 113:52-56. doi: 10.1016/j.jsbmb.2008.11.004 [7] Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer:a marked improvement in response and survival[J]. J Steroid Biochem, 1985, 23:833-841. doi: 10.1016/S0022-4731(85)80024-8 [8] Fogle RH, Stanczyk FZ, Zhang X, et al. Ovarian androgen production in postmenopausal women[J]. J Clin Endocrinol Metab, 2007, 92:3040-3043. doi: 10.1210/jc.2007-0581 [9] Couzinet B, Meduri G, Lecce MG, et al. The postmeno-pausal ovary is not a major androgen-producing gland[J]. J Clin Endocrinol Metab, 2001, 86:5060-5066. doi: 10.1210/jcem.86.10.7900 [10] Williams MR, Dawood T, Ling S, et al. Dehydroepiandro-sterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors[J]. J Clin Endocrinol Metab, 2004, 89:4708-4715. doi: 10.1210/jc.2003-031560 [11] Liu D, Dillon JS. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells:evidence for a cell surface receptor[J]. Steroids, 2004, 69:279-289. doi: 10.1016/j.steroids.2004.02.004 [12] Le Mee S, Hennebert O, Ferrec C, et al. 7beta-Hydroxy-epiandrosterone-mediated regulation of the prostaglandin synthesis pathway in human peripheral blood monocytes[J]. Steroids, 2008, 73:1148-1159. doi: 10.1016/j.steroids.2008.05.001 [13] Enomoto M, Adachi H, Fukami A, et al. Serum dehydro-epiandrosterone sulfate levels predict longevity in men:27-year follow-up study in a community-based cohort (Tanushimaru study)[J]. J Am Geriatr Soc, 2008, 56:994-998. doi: 10.1111/j.1532-5415.2008.01692.x [14] Cappola AR, O'Meara ES, Guo W, et al. Trajectories of dehydroepiandrosterone sulfate predict mortality in older adults:the cardiovascular health study[J]. J Gerontol A Biol Sci Med Sci, 2009, 64:1268-1274. http://www.ncbi.nlm.nih.gov/pubmed/19713299 [15] Ebeling P, Koivisto VA. Physiological importance of dehydroepiandrosterone[J]. Lancet, 1994, 343:1479-1481. doi: 10.1016/S0140-6736(94)92587-9 [16] Casson PR, Toth MJ, Johnson JV, et al. Correlation of serum androgens with anthropometric and metabolic indices in healthy, nonobese postmenopausal women[J]. J Clin Endocrinol Metab, 2010, 95:4276-4282. doi: 10.1210/jc.2009-2390 [17] Williams MR, Ling S, Dawood T, et al. Dehydroepiandro-sterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs[J]. J Clin Endocrinol Metab, 2002, 87:176-181. doi: 10.1210/jcem.87.1.8161 [18] Shufelt C, Bretsky P, Almeida CM, et al. DHEA-S levels and cardiovascular disease mortality in postmenopausal wo-men:results from the National Institutes of Health-National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE)[J]. J Clin Endocrinol Metab, 2010, 95:4985-4992. doi: 10.1210/jc.2010-0143 [19] Akishita M, Hashimoto M, Ohike Y, et al. Association of plasma dehydroepiandrosterone-sulfate levels with endothelial function in postmenopausal women with coronary risk factors[J]. Hypertens Res, 2008, 31:69-74. doi: 10.1291/hypres.31.69 [20] Yoshida S, Aihara K, Azuma H, et al. Dehydroepiandro-sterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function[J]. Atherosclerosis, 2010, 212:310-315. doi: 10.1016/j.atherosclerosis.2010.05.011 [21] Christiansen JJ, Andersen NH, Sorensen KE, et al. Dehydroepiandrosterone substitution in female adrenal failure:no impact on endothelial function and cardiovascular para-meters despite normalization of androgen status[J]. Clin Endocrinol (Oxf), 2007, 66:426-433. doi: 10.1111/j.1365-2265.2007.02750.x [22] Baulieu EE, Robel P, Schumacher M. Neurosteroids:beginning of the story[J]. Int Rev Neurobiol, 2001, 46:1-32. doi: 10.1016/S0074-7742(01)46057-0 [23] Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandro-sterone monotherapy in midlife-onset major and minor depression[J]. Arch Gen Psychiatry, 2005, 62:154-162. doi: 10.1001/archpsyc.62.2.154 [24] Takayanagi R, Goto K, Suzuki S, et al. Dehydroepiandro-sterone (DHEA) as a possible source for estrogen formation in bone cells:correlation between bone mineral density and serum DHEA-sulfate concentration in postmenopausal women, and the presence of aromatase to be enhanced by 1, 25-dihydroxyvitamin D3 in human osteoblasts[J]. Mech Ageing Dev, 2002, 123:1107-1114. doi: 10.1016/S0047-6374(01)00394-3 [25] Tok EC, Ertunc D, Oz U, et al. The effect of circulating androgens on bone mineral density in postmenopausal women[J]. Maturitas, 2004, 48:235-242. doi: 10.1016/j.maturitas.2003.11.007 [26] Callies F, Fassnacht M, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency:effects on body composition, serum leptin, bone turnover, and exercise capacity[J]. J Clin Endocrinol Metab, 2001, 86:1968-1972. doi: 10.1210/jcem.86.5.7483 [27] Voznesensky M, Walsh S, Dauser D, et al. The association between dehydroepiandosterone and frailty in older men and women[J]. Age Ageing, 2009, 38:401-406. doi: 10.1093/ageing/afp015 [28] Baker WL, Karan S, Kenny AM. Effect of dehydroepiandrosterone on muscle strength and physical function in older adults:a systematic review[J]. J Am Geriatr Soc, 2011, 59:997-1002. doi: 10.1111/j.1532-5415.2011.03410.x [29] Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency[J]. N Engl J Med, 1999, 341:1013-1020. doi: 10.1056/NEJM199909303411401 [30] Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency[J]. J Clin Endocrinol Metab, 2009, 94:3676-3681. doi: 10.1210/jc.2009-0672 [31] Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging:contribution of the DHEAge Study to a sociobiomedical issue[J]. Proc Natl Acad Sci USA, 2000, 97:4279-4284. doi: 10.1073/pnas.97.8.4279 [32] Jankowski CM, Gozansky WS, Kittelson JM, et al. Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens[J]. J Clin Endocrinol Metab, 2008, 93:4767-4773. doi: 10.1210/jc.2007-2614 [33] Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy[J]. N Engl J Med, 2000, 343:682-688. doi: 10.1056/NEJM200009073431002 [34] Srinivasan M, Irving BA, Frye RL, et al. Effects on lipoprotein particles of long-term dehydroepiandrosterone in elderly men and women and testosterone in elderly men[J]. J Clin Endocrinol Metab, 2010, 95:1617-1625. doi: 10.1210/jc.2009-2000 [35] Kritz-Silverstein D, von Muhlen D, Laughlin GA, et al. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life:the DHEA and Well-Ness (DAWN) Trial[J]. J Am Geriatr Soc, 2008, 56:1292-1298. doi: 10.1111/j.1532-5415.2008.01768.x [36] Yamada S, Akishita M, Fukai S, et al. Effects of dehydro-epiandrosterone supplementation on cognitive function and activities of daily living in older women with mild to moderate cognitive impairment[J]. Geriatr Gerontol Int, 2010, 10:280-287. doi: 10.1111/j.1447-0594.2010.00625.x [37] Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy[J]. Menopause, 2009, 16:907-922. doi: 10.1097/gme.0b013e31819e8e2d [38] Panjari M, Bell RJ, Jane F, et al. The safety of 52 weeks of oral DHEA therapy for postmenopausal women[J]. Maturitas, 2009, 63:240-245. doi: 10.1016/j.maturitas.2009.03.020 [39] Traish AM, Kang HP, Saad F, et al. Dehydroepiandro-sterone (DHEA)-a precursor steroid or an active hormone in human physiology (CME)[J]. J Sex Med, 2011, 8:2960-2982. doi: 10.1111/j.1743-6109.2011.02523.x
点击查看大图
计量
- 文章访问数: 143
- HTML全文浏览量: 54
- PDF下载量: 9
- 被引次数: 0